Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerardus W J Frederix

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|December 2, 2021
Cost-effectiveness of whole-exome sequencing in progressive neurological disorders of childrenJuho Aaltio, Virva Hyttinen, Mika Kortelainen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2022
Market access to new anticancer medicines for children and adolescents with cancer in EuropeReineke A Schoot, Maria A Otth, Gerardus W J Frederix, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 24, 2012
Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomesGerardus W J Frederix, Johan L Severens, Anke M Hövels, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 18, 2013
The cloudy crystal ball of cost-effectiveness studiesGerardus W J Frederix, Johan L Severens, Anke M Hövels, et al.
Journal of Medical Economics|December 17, 2021
Economic evaluations of exome and genome sequencing in pediatric genetics: considerations towards a consensus strategyRichelle A C M Olde Keizer, Lidewij Henneman, Johannes Kristian Ploos van Amstel, et al.
Clinical Therapeutics|April 2, 2013
Utility and work productivity data for economic evaluation of breast cancer therapies in the Netherlands and SwedenGerardus W J Frederix, Nuz Quadri, Anke M Hövels, et al.
Pharmacoeconomics|November 23, 2013
The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidanceGerardus W J Frederix, Johan G C van Hasselt, Jan H M Schellens, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 22, 2013
Development of a framework for cohort simulation in cost-effectiveness analyses using a multistep ordinary differential equation solver algorithm in RGerardus W J Frederix, Johan G C van Hasselt, Johan L Severens, et al.
European Journal of Human Genetics : EJHG|July 1, 2018
Whole-exome sequencing in intellectual disability; cost before and after a diagnosisTerry Vrijenhoek, Eline M Middelburg, Glen R Monroe, et al.
European Journal of Medical Genetics|March 3, 2022
Medical costs of children admitted to the neonatal intensive care unit: The role and possible economic impact of WES in early diagnosisRichelle A C M Olde Keizer, Abderrahim Marouane, A Chantal Deden, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|December 2, 2021
Cost-effectiveness of whole-exome sequencing in progressive neurological disorders of childrenJuho Aaltio, Virva Hyttinen, Mika Kortelainen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2022
Market access to new anticancer medicines for children and adolescents with cancer in EuropeReineke A Schoot, Maria A Otth, Gerardus W J Frederix, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 24, 2012
Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomesGerardus W J Frederix, Johan L Severens, Anke M Hövels, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 18, 2013
The cloudy crystal ball of cost-effectiveness studiesGerardus W J Frederix, Johan L Severens, Anke M Hövels, et al.
Journal of Medical Economics|December 17, 2021
Economic evaluations of exome and genome sequencing in pediatric genetics: considerations towards a consensus strategyRichelle A C M Olde Keizer, Lidewij Henneman, Johannes Kristian Ploos van Amstel, et al.
Clinical Therapeutics|April 2, 2013
Utility and work productivity data for economic evaluation of breast cancer therapies in the Netherlands and SwedenGerardus W J Frederix, Nuz Quadri, Anke M Hövels, et al.
Pharmacoeconomics|November 23, 2013
The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidanceGerardus W J Frederix, Johan G C van Hasselt, Jan H M Schellens, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 22, 2013
Development of a framework for cohort simulation in cost-effectiveness analyses using a multistep ordinary differential equation solver algorithm in RGerardus W J Frederix, Johan G C van Hasselt, Johan L Severens, et al.
European Journal of Human Genetics : EJHG|July 1, 2018
Whole-exome sequencing in intellectual disability; cost before and after a diagnosisTerry Vrijenhoek, Eline M Middelburg, Glen R Monroe, et al.
European Journal of Medical Genetics|March 3, 2022
Medical costs of children admitted to the neonatal intensive care unit: The role and possible economic impact of WES in early diagnosisRichelle A C M Olde Keizer, Abderrahim Marouane, A Chantal Deden, et al.
Pageof 2